Clinical trials: Nausea With Vomiting Chemotherapy-Induced
Hematologic Neoplasms, Nausea
The Effect of a Protective Oral Care Protocol Using Peppermint Oil Mouthwash
Hematologic malignancies are the fifth most common type of cancer in the world. Patients with hematologic malignancies receive long-term and exhausting treatments such as chemotherapy, radiotherapy, hematopoietic stem cell…
- Conditions
- Hematologic Neoplasms, Nausea, Vomiting, Anorexia
- Trial name
- NCT07179094
- Testing
- Routine Protective Oral Care, Protective Oral Care Using Peppermint Oil Mouthwash
- Volunteers
- 72 people
- Sponsor
- Şule Güzle
Chemotherapy-induced Nausea and Vomiting
Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)
The purpose of this study was to determine the appropriate dosing regimen of fosaprepitant, when administered with ondansetron (with or without dexamethasone), for the prevention of CINV in children from birth to <17 years of…
- Trial name
- NCT01697579
- Testing
- Fosaprepitant, Ondansetron, 5-hydroxytryptamine 3 antagonist
- Volunteers
- 240 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-induced Nausea and Vomiting
A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC
The primary study objective is to demonstrate the superiority of APF530 500 mg given subcutaneously (SC) compared with ondansetron 0.15 mg/kg given intravenously (IV) (up to a maximum of 16 mg) in the delayed-phase (> 24-120…
- Trial name
- NCT02106494
- Testing
- APF530, Ondansetron, Fosaprepitant
- Where
- 7 sites in United States
- Volunteers
- 942 people
- Sponsor
- Heron Therapeutics
Chemotherapy-induced Nausea and Vomiting
Re-examination Study of EMEND (Aprepitant) (MK-0869-184)
This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation.
- Trial name
- NCT01074255
- Testing
- EMEND
- Volunteers
- 3,546 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-induced Nausea and Vomiting
An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant
This is an open-label, randomized, single-dose, single-center, parallel-group bioequivalence study of orally- and IV-administered rolapitant in healthy male and female subjects.
- Trial name
- NCT02285647
- Testing
- Rolapitant - Oral, Rolapitant - IV
- Where
- United States
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Tesaro, Inc.
Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
This randomized phase III trial is studying APF530 and dexamethasone to see how well they work compared with palonosetron and dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for cancer.
- Trial name
- NCT00343460
- Testing
- APF530, dexamethasone, Palonosetron Hydrochloride
- Where
- 52 sites in United States
- Volunteers
- 1,428 people
- Sponsor
- Heron Therapeutics
Chemotherapy-induced Nausea and Vomiting
The Effect of Breathing Exercise on Chemotherapy-induced Nausea and Vomiting in With Autologous Hematopoietic Stem Cell Transplantation Patients
Nausea and vomiting are serious problems in patients undergoing autologous stem cell transplantation. It is stated that the incidence of acute and delayed nausea and vomiting is more than 50%, even if the patient has been given…
- Trial name
- NCT05311371
- Testing
- Breathing exercise group, Control group
- Where
- Turkey (Türkiye)
- Volunteers
- 70 people
- Sponsor
- Istanbul University - Cerrahpasa
Nausea With Vomiting Chemotherapy-Induced
BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron
Patients undergoing either an autologous or allogeneic hematopoietic stem cell transplant (HSCT) and receiving preparative chemotherapy experience a considerable amount of chemotherapy-induced nausea and vomiting (CINV).
- Trial name
- NCT04150614
- Testing
- Granisetron Transdermal Patch, Intravenous Dexamethasone, Ondansetron
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Illinois Chicago
Nausea and Vomiting Chemotherapy-Induced, Nausea Post Chemotherapy
Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)
Chemotherapy often causes nausea and vomiting (CINV), and this is a major problem for the children being treated for cancer. To prevent this, a combination of two substances in fixed proportion (IV NEPA) was developed.
- Trial name
- NCT06904235
- Testing
- IV NEPA (fosnetupitant/palonosetron), Reference Treatment: IV ondansetron infusion, Reference Treatment: IV fosaprepitant infusion
- Where
- 20 sites in Greece, Poland and 2 more
- Volunteers
- 95 people
- Sponsor
- Helsinn Healthcare SA
Nausea and Vomiting
A Phase IV Trial of Cesamet™ Given With Standard Antiemetic Therapy for Chemotherapy-induced Nausea and Vomiting
This is a Phase IV, open-label, sequential treatment study in patients who are receiving standard chemotherapy for non-small cell lung cancer, breast cancer, or colorectal cancer.
- Trial name
- NCT00418678
- Testing
- Cesamet
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Veeda Oncology
Chemotherapy-induced Nausea and Vomiting
Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC
The phase 3 study is to compare the efficacy and safety of palonosetron, a long-acting 5-HT3 receptor antagonist, by buccal film delivery compared to IV injection for the prevention of chemotherapy-induced nausea and vomiting.
- Trial name
- NCT05199818
- Testing
- Palonosetron HCl Buccal Film 0.5 mg, IV Palonosetron 0.25 mg
- Where
- 13 sites in United States
- Volunteers
- 328 people
- Sponsor
- Xiamen LP Pharmaceutical Co., Ltd
Chemotherapy-induced Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer
The goal of this clinical research study is to learn if adding dronabinol in combination with the standard of care (dexamethasone and palonosetron) can better help to control nausea and vomiting in patients receiving…
- Trial name
- NCT00553059
- Testing
- dexamethasone, dronabinol, palonosetron hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 62 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer
Personalized Electroacupuncture Treatment for Chemotherapy-induced Nausea and Vomiting in Breast Cancer (PET)
This study aims to evaluate electroacupuncture as an antiemetic treatment compared with sham acupuncture in patients with breast cancer, receiving highly emetogenic chemotherapy (HEC).
- Trial name
- NCT05275569
- Testing
- True acupuncture + standard antiemetic treatment
- Where
- China
- Volunteers
- 234 people
- Sponsor
- Affiliated Hospital of Qinghai University
Cancer
Stimulation of Auricular Acupuncture-Point for Chemotherapy-Induced Nausea/Vomiting
The purpose of this study is to evaluate auricular acupuncture as an antiemetic treatment compared with sham acupuncture and with no acupuncture in patients receiving moderately-high to highly emetogenic chemotherapy.
- Trial name
- NCT00360841
- Testing
- Auricular acupuncture
- Where
- Taiwan
- Volunteers
- 103 people
- Sponsor
- National Taiwan University Hospital
Malignant Tumor
ONO-7436 Phase II Study in Japan
The purpose of this study is to examine the efficacy and safety of ONO-7436 for the prevention of cancer chemotherapy-induced nausea and vomiting in patients with malignant tumor
- Trial name
- NCT00212602
- Testing
- ONO-7436
- Where
- 9 sites in Japan
- Volunteers
- 420 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Chemotherapy-Induced Nausea and Vomiting
An Efficacy and Safety Study of Palonosetron in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in the Chinese Cancer Patients
This clinical study was designed to demonstrate that a single, intravenous dose of palonosetron 0.25 mg was not inferior to granisetron 3 mg in preventing acute and delayed CINV and was also well tolerated in the Chinese cancer…
- Trial name
- NCT00666783
- Testing
- palonosetron, Granisetron
- Where
- China
- Volunteers
- 208 people
- Sponsor
- Xijing Hospital
Chemotherapy Induced Nausea and Vomiting Pediatric Cancer Patients
Efficacy and Safety of Fosaprepitant in Preventing Chemotherapy-induced Vomiting in Children Treated With Medium and High Emetic Chemotherapeutic Drugs
This study was a prospective, randomized, double-blind, parallel controlled clinical trial. The children who met the inclusion criteria and were treated with medium and high emetic chemotherapy drugs were randomly included in the…
- Trial name
- NCT05230654
- Testing
- Fosaprepitant
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Children's Medical Center
Chemotherapy-Induced Nausea and Vomiting (CINV), Hematopoietic Stem Cell Transplantation (HSCT)
Acupuncture to Prevent Nausea and Vomiting After Stem Cell Transplant
This study is testing whether acupuncture at a point on the wrist called "Neiguan" can help reduce nausea and vomiting in patients undergoing stem cell transplantation.
- Trial name
- NCT07747194
- Testing
- Acupuncture, Conventional care
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Xiao Wang
Chemotherapy-induced Nausea and Vomiting
Prevalence of Anticipatory Nausea and Vomiting in Cancer Patients Exposed to Highly Emetogenic Chemotherapy
Chemotherapy induced nausea and vomiting are common adverse events related to oncologic treatments. It can have deleterious effect on patients' quality of life and could lead to dose reductions and/or discontinuation of…
- Trial name
- NCT04785495
- Testing
- Quality-of-life assessment
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Instituto Brasileiro de Controle do Cancer
Chemotherapy-induced Nausea and Vomiting
A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer
Multicenter, randomized, double-blind, double-dummy, parallel group, stratified study assessing the safety and describing the efficacy of a single dose of intravenous (IV) fosnetupitant/palonosetron (260 mg/0.25 mg) infusion…
- Trial name
- NCT03403712
- Testing
- fosnetupitant/ palonosetron, netupitant/palonosetron, dexamethasone
- Where
- 40 sites in United States, Georgia
- Volunteers
- 404 people
- Sponsor
- Helsinn Healthcare SA